Par Drugs and Chemicals Limited (NSE:PAR)
India flag India · Delayed Price · Currency is INR
98.77
+1.87 (1.93%)
At close: Feb 16, 2026

Par Drugs and Chemicals Cash Flow Statement

Millions INR. Fiscal year is Apr - Mar.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '25 Mar '24 Mar '23 Mar '22 Mar '21
Net Income
133.58145.01113.3492.13116.11
Depreciation & Amortization
36.4734.3632.3332.8128.19
Loss (Gain) From Sale of Assets
--0.08-1.43--19.86
Other Operating Activities
-10.143.17-5.845.46-0.21
Change in Accounts Receivable
-3032.5514.98-60.16-0.83
Change in Inventory
-19.2912.02-6.66-17.16-0.8
Change in Accounts Payable
55.35-27.35-25.739.445.13
Change in Other Net Operating Assets
-4.362.8212.75-16.38-6.89
Operating Cash Flow
161.6202.49133.7776.15120.85
Operating Cash Flow Growth
-20.19%51.37%75.66%-36.99%57.13%
Capital Expenditures
-12.27-60.8-76.34-32.02-50.49
Sale of Property, Plant & Equipment
-0.122-49.21
Investment in Securities
-250.58-0.02--0.47
Other Investing Activities
10.482.320.961.841.33
Investing Cash Flow
-252.37-58.38-73.38-30.180.51
Short-Term Debt Issued
----32.48
Total Debt Issued
----32.48
Short-Term Debt Repaid
----32.4-
Long-Term Debt Repaid
----43.9-2.27
Total Debt Repaid
----76.3-2.27
Net Debt Issued (Repaid)
----76.330.21
Common Dividends Paid
----15.3-7.69
Dividends Paid
----15.3-7.69
Other Financing Activities
---0.02-3.9-6.03
Financing Cash Flow
---0.02-95.516.49
Miscellaneous Cash Flow Adjustments
00--0.07-
Net Cash Flow
-90.77144.1160.37-49.6137.85
Free Cash Flow
149.34141.6957.4344.1370.36
Free Cash Flow Growth
5.40%146.69%30.15%-37.28%14.73%
Free Cash Flow Margin
14.79%14.81%6.00%5.88%11.58%
Free Cash Flow Per Share
12.1411.524.673.595.72
Cash Interest Paid
--0.023.76.03
Cash Income Tax Paid
45.1743.642.6331.2435.95
Levered Free Cash Flow
121.5121.4342.5234.2450.55
Unlevered Free Cash Flow
121.5121.4342.5436.5954.32
Change in Working Capital
1.720.03-4.64-54.26-3.39
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.